|Day Low/High||84.94 / 86.29|
|52 Wk Low/High||55.36 / 90.61|
Current valuations are at record lows, despite the companies having good prospects.
On eve of earnings, successes overshadowed by losing ground to Walmart.
CVS Health shares were down Tuesday after the company reported mixed results and downside guidance.
Jim Cramer says Walgreens is the winner and CVS Health is the loser.
"Cause you had a bad day You're taking one down You sing a sad song just to turn it around You say you don't know You tell me don't lie You work at a smile and you go for a ride You had a bad day The camera don't lie You're coming back down and you ...
U.S. stocks wavered Tuesday as America headed to the polls in a closely-watched presidential election between Hillary Clinton and Donald Trump.
Investors are bracing for Tuesday's all-important U.S. presidential election between Hillary Clinton and Donald Trump.
CVS needs to change its image to move ahead, says TheStreet's Jim Cramer.
Avoid stocks with poor numbers that would suffer under a Clinton administration.
Let's take a closer look at CVS Health and Valeant Pharmaceuticals.
For the week of November 7, all eyes will be on Tuesday's presidential election.
The stock is likely to drift lower before buyers feel good about it again.
McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.
This group has become ridiculously cheap, but no one cares; watch Best Buy and TJX.
This year hasn't gone Target's way, but its smaller-store format is one way it quietly is working to build a competitive edge for the long haul.
Action Alerts PLUS holdings are preparing for a smartphone showdown, while fellow holding Walgreens could see a boost to earnings.
Problems have hit some favorite names, but opportunities are becoming apparent.
The stock has gotten off to a rousing start, but competition in the cosmetics space should cause investors to look below the surface.
ELF Beauty is now officially a public company. Here is what the company's CEO has planned to keep the company's results looking sexy.
The recent selloff doesn't track the strong economics of the business.
It doesn't seem a stretch to think CVS could rebound to $100 or better over the coming 12 months.
McKesson is down 10 percent year-to-date due to the heated political debate over drug pricing but the stock is too cheap to ignore.
The retailer's recent price weakness is an opportunity for investors to act.